Telix Pharmaceuticals Limited

ASX (AUD): Telix Pharmaceuticals Limited (TLX)

Last Price

24.91

Today's Change

+0.31 (1.26%)

Day's Change

24.50 - 25.08

Trading Volume

573,680

Profile
TLX

Exchange:  Australian Securities Exchange Australian Securities Exchange

Currency:  AUD AUD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA

Full Time Employees:  415 415

IPO Date:  2017-11-14 2017-11-14

CIK: 

ISIN:  AU000000TLX2 AU000000TLX2

CUSIP: 

Beta:  2.38 2.38

Last Dividend:  0.00 0.00

Dcf Diff:  0.00 0.00

Dcf:  0.00 0.00

Description

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Address

55 Flemington Road,
North Melbourne, VIC 3051, AU

61 3 3093 3897

http://telixpharma.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment